Mesoblast (MEOBF) Non-Current Debt (2018)
Mesoblast's (MEOBF) quarterly Non-Current Debt came in at $61.2 million in Q3 2018, up 2.97% quarter-over-quarter from $59.4 million in Q2 2018.
Analysis
Mesoblast (MEOBF) Non-Current Debt (2018) Analysis & Trends
Mesoblast has disclosed Non-Current Debt across 1 years of filings, most recently posting $61.2 million for Q3 2018.
- In Q3 2018, Non-Current Debt changed N/A year-over-year to $61.2 million; the TTM figure through Sep 2018 stood at $61.2 million (changed N/A YoY), while the FY2018 annual figure was $59.4 million, changed N/A from the prior year.
- Non-Current Debt came in at $61.2 million for Q3 2018 at Mesoblast, up from $59.4 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $61.2 million in Q3 2018 to a low of $31.4 million in Q1 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | 586.20 Mn |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | - |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | - |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | 50.15 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | 100.26 Mn |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 93.88 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 847.62 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | - |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2018 | 61.16 Mn |
| Jun 30, 2018 | 59.40 Mn |
| Mar 31, 2018 | 31.42 Mn |